135 related articles for article (PubMed ID: 8481365)
1. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mitozantrone and epirubicin in advanced breast cancer.
Cook AM; Chambers EJ; Rees GJ
Clin Oncol (R Coll Radiol); 1996; 8(6):363-6. PubMed ID: 8973851
[TBL] [Abstract][Full Text] [Related]
3. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
Perez DJ; Harvey VJ; Robinson BA; Atkinson CH; Dady PJ; Kirk AR; Evans BD; Chapman PJ
J Clin Oncol; 1991 Dec; 9(12):2148-52. PubMed ID: 1960557
[TBL] [Abstract][Full Text] [Related]
5. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
Stuart-Harris R; Simes RJ; Coates AS; Raghavan D; Devine R; Tattersall MH
Eur J Cancer Clin Oncol; 1987 May; 23(5):557-61. PubMed ID: 3653179
[TBL] [Abstract][Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Heidemann E; Steinke B; Hartlapp J; Schumacher K; Possinger K; Kunz S; Neeser E; von Ingersleben G; Hossfeld D; Waldmann R
Onkologie; 1990 Feb; 13(1):24-7. PubMed ID: 2186320
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB
Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
[TBL] [Abstract][Full Text] [Related]
16. Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin.
Herait P; Poutignat N; Marty M; Bugat R
Eur J Cancer; 1992; 28A(10):1670-6. PubMed ID: 1389483
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
[TBL] [Abstract][Full Text] [Related]
18. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma.
Nair R; Ramakrishnan G; Nair NN; Saikia TK; Parikh PM; Joshi SR; Soman CS; Mukhadan M; Dinshaw KT; Advani SH
Cancer; 1998 Jun; 82(11):2282-8. PubMed ID: 9610711
[TBL] [Abstract][Full Text] [Related]
20. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
